Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1997-9-4
|
| pubmed:abstractText |
This study was conducted to investigate the clinical utility of CEA, CA 19-9, and CA-50 in the diagnosis, monitoring, and prognosis of 62 gastric carcinoma patients having either adjuvant or palliative chemotherapy. Patients were divided in two groups: group A included patients treated on an adjuvant basis following a curative resection of gastric cancer, and group B included patients with residual disease post surgery or patients with inoperable tumor or generalized disease. Serum marker levels were measured in a prospective study just before the initiation of chemotherapy and before each course during chemotherapy. In group A, CEA was positive in 2/25 (8%) patients, CA 19-9 in 1/25 (4%), and CA-50 in 1/25 (4%). In group B the sensitivity of CEA was 48.6% (18/37 patients), of CA 19-9 64.9% (27/37 patients), and of CA-50 70.3% (26/37) patients. There was a significant correlation between the CA 19-9 and CA-50 levels in both groups. No correlation was found between the sensitivity or the absolute initial marker levels and the tumor's differentiation or extent of disease. In group A the only patient with initially elevated CA 19-9 and CA-50 values relapsed early while he was on adjuvant chemotherapy. It was also found that the rising final CA 19-9 and CA-50 values at the end of chemotherapy were correlated with an increased incidence of relapse, but not with the disease-free interval. In group B the initially low marker levels showed a trend to predict a favorable outcome of treatment. There was no statistically significant correlation between the marker titers before each course and response to chemotherapy. It is concluded that the comeasurement of CA 19-9 and CA-50, and to some degree of CEA, is justifiable for gastric cancer. The estimation of CA 19-9 and CA-50 may be useful for early detection of recurrence after curative surgery and adjuvant chemotherapy. In advanced or recurrent gastric cancer, the estimation of either CA 19-9 or CA-50 and CEA serum values may help in checking the prognosis, determining the efficacy of palliative treatment modalities, and recognizing recurrences.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Tumor-Associated...,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic,
http://linkedlifedata.com/resource/pubmed/chemical/CA-19-9 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/CA-50 antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Carcinoembryonic Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Epirubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0277-3732
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
20
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
348-53
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:9256887-Adult,
pubmed-meshheading:9256887-Aged,
pubmed-meshheading:9256887-Antibiotics, Antineoplastic,
pubmed-meshheading:9256887-Antigens, Tumor-Associated, Carbohydrate,
pubmed-meshheading:9256887-Antineoplastic Agents,
pubmed-meshheading:9256887-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:9256887-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9256887-CA-19-9 Antigen,
pubmed-meshheading:9256887-Carcinoembryonic Antigen,
pubmed-meshheading:9256887-Carcinoma,
pubmed-meshheading:9256887-Chemotherapy, Adjuvant,
pubmed-meshheading:9256887-Cisplatin,
pubmed-meshheading:9256887-Disease-Free Survival,
pubmed-meshheading:9256887-Epirubicin,
pubmed-meshheading:9256887-Etoposide,
pubmed-meshheading:9256887-Female,
pubmed-meshheading:9256887-Humans,
pubmed-meshheading:9256887-Incidence,
pubmed-meshheading:9256887-Male,
pubmed-meshheading:9256887-Middle Aged,
pubmed-meshheading:9256887-Neoplasm, Residual,
pubmed-meshheading:9256887-Neoplasm Recurrence, Local,
pubmed-meshheading:9256887-Neoplasm Staging,
pubmed-meshheading:9256887-Palliative Care,
pubmed-meshheading:9256887-Prognosis,
pubmed-meshheading:9256887-Prospective Studies,
pubmed-meshheading:9256887-Sensitivity and Specificity,
pubmed-meshheading:9256887-Stomach Neoplasms,
pubmed-meshheading:9256887-Treatment Outcome,
pubmed-meshheading:9256887-Tumor Markers, Biological
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma.
|
| pubmed:affiliation |
First Department of Medical Oncology, Metaxas Memorial Cancer Hospital, Piraous, Greece.
|
| pubmed:publicationType |
Journal Article
|